While the prevalence of cancer is increasing secondary, in part due to the advent of new diagnostic techniques, the incidence of cancer pain does not seem to be decreasing despite progress in the development of targeted cancer therapies.

Assessments of cancer pain must be multifactorial and patient-centered; treatment is largely dependent on pharmacotherapy.

Future research should utilize patient-reported outcome measurements to drive the improvement of assessment tools and the development of new treatment options for the management of cancer pain, including neuraxial anesthesia and neuroablative techniques.